- Home
- DCGO vs ALDX Comparison
DCGO vs ALDX Comparison
Compare DCGO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- ALDX
- Stock Information
- Founded
- DCGO 2015
- ALDX 2004
- Country
- DCGO United States
- ALDX United States
- Employees
- DCGO N/A
- ALDX N/A
- Industry
- DCGO Managed Health Care
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- DCGO Health Care
- ALDX Health Care
- Exchange
- DCGO Nasdaq
- ALDX Nasdaq
- Market Cap
- DCGO 144.7M
- ALDX 270.7M
- IPO Year
- DCGO N/A
- ALDX 2014
- Fundamental
- Price
- DCGO $1.42
- ALDX $5.05
- Analyst Decision
- DCGO Strong Buy
- ALDX Strong Buy
- Analyst Count
- DCGO 4
- ALDX 2
- Target Price
- DCGO $3.74
- ALDX $9.50
- AVG Volume (30 Days)
- DCGO 459.6K
- ALDX 1.2M
- Earning Date
- DCGO 08-07-2025
- ALDX 08-04-2025
- Dividend Yield
- DCGO N/A
- ALDX N/A
- EPS Growth
- DCGO N/A
- ALDX N/A
- EPS
- DCGO N/A
- ALDX N/A
- Revenue
- DCGO $520,500,658.00
- ALDX N/A
- Revenue This Year
- DCGO N/A
- ALDX N/A
- Revenue Next Year
- DCGO $4.08
- ALDX N/A
- P/E Ratio
- DCGO N/A
- ALDX N/A
- Revenue Growth
- DCGO N/A
- ALDX N/A
- 52 Week Low
- DCGO $1.23
- ALDX $1.14
- 52 Week High
- DCGO $5.68
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- DCGO 43.13
- ALDX 61.12
- Support Level
- DCGO $1.42
- ALDX $5.21
- Resistance Level
- DCGO $1.54
- ALDX $5.66
- Average True Range (ATR)
- DCGO 0.08
- ALDX 0.31
- MACD
- DCGO 0.00
- ALDX -0.07
- Stochastic Oscillator
- DCGO 32.56
- ALDX 45.25
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.